Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
暂无分享，去创建一个
F. Ravandi | A. Wei | R. Walter | M. Subklewe | A. Hindoyan | S. Agarwal | D. Ritchie | R. Bhatia | A. Stein | V. Bücklein | A. Anderson | S. Khaldoyanidi | P. Vachhani | T. Dai | Veit L Bücklein